Lundbeck to highlight mechanistic insights on bexicaserin's dual mode of action at the European Epilepsy Congress

Summary

Lundbeck will present preclinical mechanistic data on bexicaserin at the European Epilepsy Congress, demonstrating the drug's dual mode of action in increasing inhibitory while decreasing excitatory neuronal activity across focal, generalized motor, and absence seizure models.